Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Thierry Façon, Gian Matteo Pica et al.|The Lancet Oncology|2025Cited by 13
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 TrialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|SSRN Electronic Journal|2025Cited by 1
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myelomaBenjamin Podvin, Salomon Manier, Holly Lee et al.|Blood Advances|2026Cited by 0